ライフサイエンスコーパス: lipogenic

1 The pro-lipogenic action of LPA is mediated through LPA(2), an L

2 s and human skin organ culture inhibited the lipogenic actions of various compounds, including arachi

3 Here we report that SREBP-1c, a key lipogenic activator, is an in vivo target of SIRT1.

4 By this method, we revealed changes in the lipogenic activity and LD sizes during glucose starvatio

5 FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

6 ated SREBP-1c acetylation increases SREBP-1c lipogenic activity in obese mice.

7 adipose tissue, possesses both lipolytic and lipogenic activity in vitro and localizes to the surface

8 To elucidate the molecular basis of anti-lipogenic activity of LCB, the expression of several gen

9 ment of LDs reflected variations in cellular lipogenic activity, and changes in the average speed of

10 r for unsaturated fatty acids that regulates lipogenic activity.

11 n the fed state to promote the expression of lipogenic and cholesterogenic genes and facilitate fat s

12 had activated microglia and up-regulation of lipogenic and cholesterogenic genes, likely adaptations

13 lin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors an

14 White adipose tissue (WAT) is not only a lipogenic and fat storage tissue but also an important e

15 er RNA expression levels of several critical lipogenic and gluconeogenic genes were significantly dec

16 used to measure triglyceride, expression of lipogenic and gluconeogenic genes, and activity of prote

17 in healthy flies and promotes expression of lipogenic and glycogenic enzymes.

18 of gene expression with increased levels of lipogenic and glycolytic enzymes.

19 n as MLXIPL), a transcriptional regulator of lipogenic and glycolytic genes.

20 In contrast, the ability of MR to regulate lipogenic and integrated stress response genes in liver

21 Consistent with these findings, lipogenic and lipid uptake genes were downregulated and

22 (WAT) involved a depot-specific induction of lipogenic and oxidative genes and a commensurate increas

23 c lipidosis partly through downregulation of lipogenic and/or upregulation of beta-oxidation transcri

24 These gluconeogenic, lipogenic, and inflammatory pathway transcripts were sim

25 PNPLA3 may function primarily in a lipogenic capacity and inhibition of PNPLA3 may be a nov

26 During MFD, lipogenic capacity and transcription of key mammary lipo

27 Cancer cells have enhanced lipogenic capacity characterized by increased synthesis

28 d increased in adipose tissue, where de novo lipogenic capacity is concomitantly enhanced.

29 Fructose is a lipogenic carbohydrate that contributes to insulin resis

30 Under lipogenic conditions of fasting/re-feeding a fat-free di

31 RH-1 promotes the development of NAFLD under lipogenic conditions through regulation of OSBPL3.

32 fragmentation and fusion under lipolytic and lipogenic conditions, respectively.

33 thway under Western HFHC dietary and de novo lipogenic conditions.

34 ng that the enzyme is highly regulated under lipogenic conditions.

35 found in Acc2(-/-) mutant mice under de novo lipogenic conditions.

36 deliver SNAP-23 to the SNARE complexes under lipogenic conditions.

37 Akt activity, leading to a self-perpetuating lipogenic cycle.

38 Among the up-regulated genes are the anti-lipogenic deacetylase sirtuin 1 (Sirt1) and the anti-lip

39 These lipogenic defects are consistent with the down-regulatio

40 thesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and t

41 A high-sucrose lipogenic diet stimulated hepatic Pnpla3 and Pnpla5 mRNA

42 osis, obesity and insulin resistance under a lipogenic diet.

43 metabolism stemming from high adiposity and lipogenic diets.

44 Fructose is considered lipogenic due to its ability to generate triglycerides a

45 ssion of ATGL in these cells antagonized the lipogenic effect of TSC2 knockout.

46 Notably, CRTC1 also mediates anti-lipogenic effects of bile acid signaling, whereas it is

47 portant role for C/EBPalpha in mediating the lipogenic effects of hepatic Trib1 deletion and provide

48 on, alleviates both anti-adipogenic and anti-lipogenic effects of Hh in cell culture models.

49 hat insulin is required specifically for the lipogenic effects of LXRalpha and that manipulation of t

50 ar whether PNPLA3 functions as a lipase or a lipogenic enzyme and whether PNPLA3 is involved in the p

51 Fatty acid synthase (FASN) is a key lipogenic enzyme catalyzing the terminal steps in the de

52 se (CCTalpha) is a proteolytically sensitive lipogenic enzyme containing an NH(2)-terminal nuclear lo

53 tent concomitant with increased Nrf2 and pro-lipogenic enzyme expression at W5 and W39 in female offs

54 ), a transcriptional repressor that inhibits lipogenic enzyme expression via a SREBP-1c-independent m

55 FGF-19 inhibition of lipogenic enzyme expression was not mediated by alterati

56 ivating SREBP-1, which subsequently enhanced lipogenic enzyme expression.

57 Unexpectedly, the lipogenic enzyme fatty acid synthase (FAS) was increased

58 ipid accumulation and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those t

59 leads to repression of LXR-mediated hepatic lipogenic enzyme gene expression.

60 The increase in lipogenic enzyme levels was accompanied by up-regulation

61 The lipogenic enzyme stearoyl-CoA desaturase 1 is highly ind

62 in plasma, reflecting a high activity of the lipogenic enzyme stearoyl-CoA desaturase-1 (SCD-1), has

63 Fatty acid synthase (FASN) is a lipogenic enzyme that is highly expressed in different h

64 In addition to lipogenic enzymes (Acc, Fasn, Scd1), the expression of t

65 e and protein expression measurements of key lipogenic enzymes [acetyl CoA carboxylase 1 (ACC1), fatt

66 Targeted inhibition of lipogenic enzymes abolished expression of CD44, a transm

67 Significant up-regulation of lipogenic enzymes and an elevation in hepatic peroxisome

68 In addition, inhibition of lipogenic enzymes and reduced expression of CD44 attenua

69 The changes in these key lipogenic enzymes are critical for the development and m

70 response is mediated by upregulation of key lipogenic enzymes by the liver X receptor.

71 that impair gluconeogenic enzymes and spare lipogenic enzymes in diet-induced obesity (DIO) are obsc

72 duction of lipogenesis and expression of key lipogenic enzymes in human fibroblasts occurs by 24 h po

73 etion upregulates liver lipid deposition and lipogenic enzymes in the mouse model.

74 <0.001] up-regulating the gene expression of lipogenic enzymes in white adipose tissue.

75 e translational activation of mRNAs encoding lipogenic enzymes late in the cell cycle including Acc1p

76 effect of AICAR, whereas inhibition of these lipogenic enzymes mimicked AMPK activation, thus demonst

77 cribed, the impact of aberrant activation of lipogenic enzymes on cancer progression remains unknown.

78 ated with tumor expression of glycolytic and lipogenic enzymes, glucose uptake, and proliferation mar

79 ves coordinate transcriptional activation of lipogenic enzymes, including fatty acid synthase and gly

80 turn, SREBP1 regulates the expression of key lipogenic enzymes, including stearoyl CoA desaturase 1 (

81 ifferentiation, expressed multiple genes for lipogenic enzymes, responded to androgen, and continued

82 decreased levels of de novo lipogenesis and lipogenic enzymes, supporting the notion that BMAL1 regu

83 sive expression of hepatic gluconeogenic and lipogenic enzymes.

84 sufficient to elevate the levels of mRNA of lipogenic enzymes.

85 (AMPK) activity, and increased expression of lipogenic enzymes.

86 and reduced expression of gluconeogenic and lipogenic enzymes.

87 thesis, through E2F1-dependent regulation of lipogenic enzymes.

88 ciated with a reduction in the expression of lipogenic enzymes.

89 ssociated with a decreased expression of key lipogenic enzymes/mediators, and improved glucose metabo

90 ac UCP3 expression through activation of the lipogenic factor SREBP-1.

91 neration of oxysterol ligands for LXR, a key lipogenic factor.

92 s in liver, which was associated with higher lipogenic factors Ppargamma, Lxr, Fasn, Scd1, and CD36.

93 An excessive lipogenic flux due to chronic dietary stimulation contri

94 by PGC1alpha, thus linking the oxidative and lipogenic functions of PGC1alpha.

95 nd subsequent acetylation in insulin-induced lipogenic gene activation.

96 ly inhibits lipid accumulation by preventing lipogenic gene engagement, without affecting PPARgamma p

97 ur results reveal that XBP1s reduces hepatic lipogenic gene expression and improves hepatosteatosis i

98 itutive activation of mTORC1 reduced hepatic lipogenic gene expression and produced hypotriglyceridem

99 document that XBP1s leads to suppression of lipogenic gene expression and reduction of hepatic trigl

100 iver of obese mice significantly reduces the lipogenic gene expression and the triglyceride content i

101 that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly supp

102 that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly supp

103 twork and absence of bile acid repression of lipogenic gene expression in livers of Cyp7a1-tg mice.

104 PRIM mice featured increased lipogenic gene expression in the liver and adipose tissu

105 and acute hepatic depletion of Bmal1 reduced lipogenic gene expression in the liver upon refeeding.

106 Decreased lipogenic gene expression resulted in a significant redu

107 fatty acid oxidation, MKP-1 promotes hepatic lipogenic gene expression through PPARgamma.

108 The induction of lipogenic gene expression was attenuated in the L-S6K-KD

109 zed by decreased insulin signaling, enhanced lipogenic gene expression, and hepatosteatosis.

110 mpaired fatty acid beta-oxidation, decreased lipogenic gene expression, and increased lipid storage c

111 605906 did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-a

112 ma insulin levels, BKS-db mice exhibit lower lipogenic gene expression, rate of lipogenesis, hepatic

113 ts show that LSD1 plays a role in regulating lipogenic gene expression, suggesting LSD1 as a potentia

114 elevated SREBP-1c acetylation and increased lipogenic gene expression, suggesting that abnormally el

115 carboxylase activity; it also down-regulates lipogenic gene expression, suppresses gluconeogenesis, a

116 and glucose homeostasis and reduced hepatic lipogenic gene expression, which was absent with the LR

117 deoxycholic acid (UDCA) inhibits LXR-induced lipogenic gene expression.

118 o have both positive and negative effects on lipogenic gene expression.

119 ently suppressed insulin and feeding-induced lipogenic gene expression.

120 d adipocyte size resulted from inhibition of lipogenic gene expression.

121 ipocytes, decreased food intake, and reduced lipogenic gene expression.

122 with increased beta-oxidation and decreased lipogenic gene expression.

123 eased acetylation of SREBP-1c with increased lipogenic gene expression.

124 t and lipogenesis by reducing glycolytic and lipogenic gene expression.

125 E (Ad-SMILE) attenuated fat accumulation and lipogenic gene induction in the liver of T7 administered

126 onsistent with the development of steatosis, lipogenic gene induction was significantly increased in

127 specific chromatin remodeling component for lipogenic gene transcription in liver.

128 insulin-signaling pathway(s) that control(s) lipogenic gene transcription via these factors have rece

129 increased hepatic triglyceride (TG) content, lipogenic gene transcription, and de novo lipogenesis.

130 and fatty acid synthase (FASN), its effector lipogenic gene.

131 Acetate predominately activates lipogenic genes ACACA and FASN expression by increasing

132 inding protein that govern the expression of lipogenic genes also followed a nonmonotonic dose-respon

133 riptional factors that control expression of lipogenic genes and adipocyte differentiation.

134 jection further increased baseline levels of lipogenic genes and decreased the levels of oxidative ge

135 pid accumulation, along with upregulation of lipogenic genes and downregulation of genes related to f

136 This innate pathway induces lipogenic genes and enhances core-associated lipid dropl

137 on with a reduction in hepatic expression of lipogenic genes and improvement in liver insulin sensiti

138 icrosomal triglyceride transfer protein, and lipogenic genes and in part by posttranscriptional effec

139 we show that myostatin directly up-regulated lipogenic genes and increased fat accumulation in cultur

140 stimulates SREBP-1-meidated transcription of lipogenic genes and lipid production in breast cancer ce

141 ed that SREBP1 cleavage and the induction of lipogenic genes and lipid synthesis are all inhibited in

142 ersely associated with the expression of key lipogenic genes and measures of lipogenesis.

143 HDAC3 depletion in mouse liver upregulates lipogenic genes and results in severe hepatosteatosis.

144 LCN13 inhibited the expression of important lipogenic genes and stimulated the genes that promote be

145 mice had increased DNA-bound C/EBPalpha near lipogenic genes and the Trib1 gene, which itself was tra

146 ic capacity and transcription of key mammary lipogenic genes are coordinately down-regulated.

147 In Tnmd transgenic mice, lipogenic genes are upregulated in eWAT, as is Ucp1 in b

148 r the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc)

149 ator, hepatic loss of HNF6 up-regulated many lipogenic genes bound directly by HNF6.

150 activation that subsequently down-regulates lipogenic genes but up-regulates fatty acid oxidation-as

151 ms differentially regulate the expression of lipogenic genes by modulating the association of the act

152 increase in lipid uptake, triglycerides, and lipogenic genes compared with macroH2A1.1.

153 tants can rescue hepatosteatosis and repress lipogenic genes expression in HDAC3-depleted mouse liver

154 l size and the expression of some adipogenic/lipogenic genes in a subset of subjects who underwent a

155 , insulin sensitivity, and the expression of lipogenic genes in abdominal subcutaneous adipose and li

156 Expression levels of adipogenic and lipogenic genes in adipose tissues were also dramaticall

157 We examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma

158 es in brown adipose tissue and oxidative and lipogenic genes in inguinal WAT.

159 alpha, and LXRalpha was unable to induce the lipogenic genes in the absence of insulin.

160 Thus, insulin was unable to induce the lipogenic genes in the absence of Lxralpha, and LXRalpha

161 tor PPARdelta controls diurnal expression of lipogenic genes in the dark/feeding cycle.

162 sensor and, along with ChREBP, may activate lipogenic genes in the fed state.

163 s are consistent with the down-regulation of lipogenic genes in the KO mice.

164 riacylglycerol levels and the mRNA levels of lipogenic genes in the liver and skeletal muscle.

165 iet produced a coordinated downregulation of lipogenic genes in the liver, resulting in a correspondi

166 LPI increased the expression of lipogenic genes in visceral adipose tissue explants and

167 limit diet-induced weight gain and suppress lipogenic genes in WAT, indicating that RSL1 balances me

168 r circadian clock, up-regulate expression of lipogenic genes only under fed conditions at Zeitgeber t

169 of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.

170 C/EBPbeta-RNAi normalized lipogenic genes sterol regulatory element-binding protei

171 mmasome is required for the up-regulation of lipogenic genes such as 3-hydroxy-3-methylglutaryl-coenz

172 nificantly higher level of expression of all lipogenic genes than the counterpart population from non

173 tes lipogenesis by activating glycolytic and lipogenic genes through the Mondo/ChREBP-Mlx transcripti

174 Gene expression of proadipogenic and lipogenic genes was altered in fat tissue of rats at 2 w

175 Hepatic expression of key glycolytic and lipogenic genes was higher in HFD-fed TG and lower in KO

176 Similarly, a set of key gluconeogenic and lipogenic genes was regulated nearly normally by feeding

177 early mouse pregnancy, expression of hepatic lipogenic genes was up-regulated and uncoupled from the

178 dipose tissue expression of inflammatory and lipogenic genes were determined.

179 ed expression of stress-related proteins and lipogenic genes were dramatically reduced.

180 a oxidation were decreased, whereas those of lipogenic genes were increased by the prolonged exposure

181 However, lipogenic genes were not differentially expressed in the

182 ion in lipid synthesis and the expression of lipogenic genes without a corresponding reduction in the

183 acid oxidation, and decreases expression of lipogenic genes, causing increased plasma HDL and decrea

184 f) livers showed hepatomegaly, activation of lipogenic genes, exacerbated steatosis and liver injury,

185 xpression of SREBP1, the master regulator of lipogenic genes, in MCF10A significantly enhanced lipoge

186 eatment suppresses the expression of several lipogenic genes, including ACLY, MIG12, FASN and NR1D1,

187 E2F1 directly binds to the promoters of key lipogenic genes, including Fasn, but does not bind direc

188 stem that promotes the hepatic expression of lipogenic genes, including stearoyl-CoA desaturase-1 (SC

189 oss of Nrf2 resulted in greater induction of lipogenic genes, lower expression of beta-oxidation gene

190 transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox.

191 As the key transcriptional activators of lipogenic genes, such as fatty acid synthase (FAS), ster

192 Significantly high levels of lipogenic genes, such as sterol regulatory element-bindi

193 id synthesis through increased expression of lipogenic genes, thereby contributing to hepatic steatos

194 gnaling pathway leads to intron retention of lipogenic genes, which triggers nonsense-mediated mRNA d

195 ase (FAS) activity and hepatic expression of lipogenic genes.

196 rimethylation (H3K4me3) with the promoter of lipogenic genes.

197 EBP processing, and subsequent expression of lipogenic genes.

198 uced hepatic expression of gluconeogenic and lipogenic genes.

199 d fish showed activation of inflammatory and lipogenic genes.

200 0.05) and a 2-3-fold increased expression of lipogenic genes.

201 mice and reduced the expression of numerous lipogenic genes.

202 remodel chromatin structure and to activate lipogenic genes.

203 cumulation; and (4) diminished expression of lipogenic genes.

204 er the nucleus to transcriptionally activate lipogenic genes.

205 ad reduced rosiglitazone-induced activity at lipogenic genes.

206 eased mRNA and protein expression of several lipogenic genes.

207 /) hepatocytes induced expression of several lipogenic genes.

208 asing its stability and its occupancy at the lipogenic genes.

209 evels of SREBP-2 and FGF21 without affecting lipogenic genes.

210 tent fat accumulation via hypomethylation of lipogenic genes.

211 uced equivalent, non-additive effects on the lipogenic genes.

212 y regulates expression of key glycolytic and lipogenic genes.

213 c, as excessive activation of aPKC-dependent lipogenic, gluconeogenic and proinflammatory pathways in

214 sponse element-binding protein (ChREBP) is a lipogenic glucose-sensing transcription factor with unkn

215 teatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet.

216 We examined levels of liver fat, lipogenic indices, markers of inflammation, serum levels

217 elated with down-regulation of lipolysis and lipogenic indices.

218 This lipogenic induction involves coordinate transcriptional

219 o a heart failure phenotype in an adult-like lipogenic milieu.

220 t phosphorylation of glycogenic GSK3beta and lipogenic mTOR was elevated.

221 metabolic profile analysis, we identified a lipogenic network that involves SCD and palmitate signal

222 of SIRT1 and SIRT1-regulated genes encoding lipogenic or fatty acid oxidation enzymes.

223 e time-controlled labeling and monitoring of lipogenic or myogenic populations of lung fibroblasts du

224 de accumulation through an inhibition of the lipogenic pathway but also led, unexpectedly, to hypothe

225 ty-acid synthase, three key functions in the lipogenic pathway in Atf4(-/-) mice.

226 yclin C (CycC) as negative regulators of the lipogenic pathway in Drosophila, mammalian hepatocytes,

227 Our study also documents decreased lipogenic pathway in mesenteric adipose tissue after HFD

228 Together, these results identify a key lipogenic pathway in SMCs that mediates vascular calcifi

229 re we identify a PPARdelta-dependent de novo lipogenic pathway in the liver that modulates fat use by

230 sis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by

231 he regulation of the enzymes involved in the lipogenic pathway under Western HFHC dietary and de novo

232 k immunological signals from TCR and IL-2 to lipogenic pathways and functional fitness, and highlight

233 Harnessing lipogenic pathways and rewiring acyl-CoA and acyl-ACP (a

234 levels of lipids and glucose, but continued lipogenic pathways and robust extracellular signal-regul

235 r to mediate these changes via lipolytic and lipogenic pathways in adipose tissue.

236 Activation of these lipogenic pathways is linked to increased de novo lipid

237 tic immune system and development of de novo lipogenic pathways that persist in vitro and may be an i

238 hways that become insulin-resistant but also lipogenic pathways that remain insulin-responsive, as we

239 rized by downregulation of Akt signaling and lipogenic pathways.

240 Since a remarkable lipogenic phenotype characterizes liver lesions from AKT

241 while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R mice.

242 with malignancy, including development of a lipogenic phenotype.

243 l mouse model that demonstrates directly how lipogenic phenotypes commonly associated with diet-induc

244 This study proposed to investigate the anti-lipogenic potential of a newly developed citrus flavonoi

245 s from nitrogen starvation and unleashed the lipogenic potential of Y. lipolytica Taken together, the

246 TDAG51(-/-) preadipocytes exhibited greater lipogenic potential.

247 tein binding to U1-70K to induce splicing of lipogenic pre-mRNAs.

248 expression of thermogenic genes, the de novo lipogenic program and the lipases ATGL and HSL.

249 findings indicate that rexinoids activate a lipogenic program in mammary epithelial cells through a

250 s role in metabolic adaption to activate the lipogenic program in response to feeding and insulin.

251 gnaling, suggesting that PPARdelta-regulated lipogenic program may protect against lipotoxicity.

252 y element-binding protein (SREBP)-1-mediated lipogenic program.

253 anscription factor that activates the entire lipogenic program.

254 ndings indicate that miR-29 controls hepatic lipogenic programs, likely in part through regulation of

255 gulation of the hepatic gluconeogenic and/or lipogenic programs, respectively.

256 lent to glucose, fructose appears to be more lipogenic, promoting dyslipidemia, fatty liver disease,

257 ich leads us to conclude that XBP1s has anti-lipogenic properties in the liver.

258 postabsorptive humans and whether adipocyte lipogenic proteins (CD36, acyl-CoA synthetases, and diac

259 element-binding protein 1 and key downstream lipogenic proteins and enzymes in fatty acid synthesis w

260 d expression of genes encoding lipolytic and lipogenic proteins.

261 pproximately 50%, due to a decrease in basal lipogenic rate and increase in basal lipolytic rate.

262 owed strong sensitivity to variations in the lipogenic rate constants.

263 increased insulin sensitivity and increased lipogenic rates, whereas adipocytes of females demonstra

264 ve-element-binding protein (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), it

265 This lipogenic response is unique, and is not duplicated by h

266 causes overactivation of the SREBP-dependent lipogenic response to feeding, exacerbating diet-induced

267 nuclear SREBP-1c abundance, and blunted the lipogenic response to feeding, LXR agonist treatment, or

268 ian clock components anticipatorily regulate lipogenic responses to feeding.

269 ride and DAG content, supporting a potential lipogenic role of PNPLA3 in humans.

270 of TAG storage in LDs LDAH plays a primarily lipogenic role, inducing LD growth and enhancing degrada

271 ereas the other two subtypes (glycolytic and lipogenic) showed distinct metabolite levels associated

272 as biohydrogenation intermediate responsive lipogenic signaling pathway for ruminants and rodents.

273 the activation of IKK-alpha and a cascade of lipogenic signaling to facilitate lipid droplet biogenes

274 epatic steatosis through attenuating hepatic lipogenic signaling.

275 co-opt a lipolytic enzyme to translate their lipogenic state into an array of protumorigenic signals.

276 2 diabetes, and cancer require a Fasn-driven lipogenic state, we propose that eIF6 could be a therape

277 LPCAT1 is the first lipogenic substrate for beta-TrCP, and the results sugge

278 In PDAC clinical samples, the lipogenic subtype associated with the epithelial (classi

279 The glycolytic and lipogenic subtypes showed striking differences in glucos

280 Conversely, we observed a myogenic-to-lipogenic switch during fibrosis resolution.

281 he activation of SREBP-1c and its downstream lipogenic target enzymes.

282 eas phenotype, whereas suppressing dSREBP or lipogenic target gene function in eas hearts rescues the

283 ding protein (ChREBP) and its glycolytic and lipogenic target genes was abnormally elevated.

284 (LXRalpha) with increased expression of its lipogenic targets Srebp1c, Chrebp, Lpk, Dgat, Fasn and S

285 s transcriptional targets both in cancer and lipogenic tissue.

286 is a protein that is abundantly expressed in lipogenic tissues and is regulated in a manner similar t

287 and TAG synthesis is coordinately induced in lipogenic tissues by feeding and insulin treatment.

288 Our data demonstrate a lipogenic-to-myogenic switch in fibroblastic phenotype d

289 SREBP1c is a key lipogenic transcription factor activated by insulin in t

290 c deacetylase sirtuin 1 (Sirt1) and the anti-lipogenic transcription factor aryl hydrocarbon receptor

291 se tissue (WAT) to control expression of the lipogenic transcription factor ChREBPbeta.

292 umulation by promoting the activation of the lipogenic transcription factor SREBP and by controlling

293 ted receptor gamma 2 (PPAR-gamma2), a potent lipogenic transcription factor, in the SHP(-/-) liver.

294 at reduces ER stress, has been proposed as a lipogenic transcription factor.

295 aused the modulation of a complex network of lipogenic transcription factors and enzymes, including S

296 decreased reporter gene activity of several lipogenic transcription factors such as peroxisome proli

297 nd CCAAT/enhancer-binding protein alpha, key lipogenic transcription factors, and reduced the lipid c

298 o displayed a reduction in the expression of lipogenic transcription factors, especially sterol-regul

299 es with the expression of genes regulated by lipogenic transcription factors, most prominently liver

300 cytes can efficiently model development of a lipogenic tumor phenotype.